---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-168287"
form_type: "8-K"
ticker: "KYTX"
cik: "0001994702"
company_name: "Kyverna Therapeutics, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:56:45.195636+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "medium"
source: SEC EDGAR
---

# Kyverna reports positive miv-cel Phase 2 data in gMG and registrational SPS trial

## Summary
- KYSA-6 Phase 2/3 trial of miv-cel in generalized myasthenia gravis: positive longer-term follow-up from Phase 2 portion.
- KYSA-8 registrational trial of miv-cel in stiff person syndrome achieved positive primary analysis results.
- Conference call held April 22, 2026 to review both data sets; slides furnished as Exhibit 99.1.
- Data presented at AAN 2026 annual meeting.

## SEC filing metadata
- accession: 0001193125-26-168287
- form_type: 8-K
- ticker: KYTX
- cik: 0001994702
- company_name: Kyverna Therapeutics, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1994702/000119312526168287/0001193125-26-168287-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1994702/000119312526168287/d100817d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-168287
- JSON: https://secwatch.observer/filing/0001193125-26-168287.json
- Plain text: https://secwatch.observer/filing/0001193125-26-168287.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.